These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
965 related articles for article (PubMed ID: 11157012)
1. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. Brito RA; Valero V; Buzdar AU; Booser DJ; Ames F; Strom E; Ross M; Theriault RL; Frye D; Kau SW; Asmar L; McNeese M; Singletary SE; Hortobagyi GN J Clin Oncol; 2001 Feb; 19(3):628-33. PubMed ID: 11157012 [TBL] [Abstract][Full Text] [Related]
2. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Kuerer HM; Newman LA; Buzdar AU; Hunt KK; Dhingra K; Buchholz TA; Binkley SM; Ames FC; Feig BW; Ross MI; Hortobagyi GN; Singletary SE Am J Surg; 1998 Dec; 176(6):502-9. PubMed ID: 9926779 [TBL] [Abstract][Full Text] [Related]
3. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586 [TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Pergolizzi S; Adamo V; Russi E; Santacaterina A; Maisano R; Numico G; Palazzolo C; Ferraù F; Settineri N; Altavilla G; Girlando A; Spadaro P; Cascinu S Int J Radiat Oncol Biol Phys; 2006 May; 65(1):25-32. PubMed ID: 16446058 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
6. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital. Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600 [TBL] [Abstract][Full Text] [Related]
7. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Touboul E; Buffat L; Lefranc JP; Blondon J; Deniaud E; Mammar H; Laugier A; Schlienger M Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1019-28. PubMed ID: 8600084 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316 [TBL] [Abstract][Full Text] [Related]
9. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929 [TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452 [TBL] [Abstract][Full Text] [Related]
12. Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Touboul E; Lefranc JP; Blondon J; Buffat L; Deniaud E; Belkacémi Y; Benmiloud M; Huart J; Laugier A; Schlienger M Radiother Oncol; 1997 Mar; 42(3):219-29. PubMed ID: 9155070 [TBL] [Abstract][Full Text] [Related]
13. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Hortobagyi GN; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Buchholz TA Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):351-7. PubMed ID: 15890574 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of nodal involvement region in clinical stage IIIc breast cancer patients who received primary systemic treatment, surgery, and radiotherapy. Noh JM; Kim KH; Park W; Suh CO; Huh SJ; Choi DH; Keum KC; Kim YB Breast; 2015 Oct; 24(5):637-41. PubMed ID: 26283599 [TBL] [Abstract][Full Text] [Related]
15. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study. Budd GT; Green S; O'Bryan RM; Martino S; Abeloff MD; Rinehart JJ; Hahn R; Harris J; Tormey D; O'Sullivan J J Clin Oncol; 1995 Apr; 13(4):831-9. PubMed ID: 7707108 [TBL] [Abstract][Full Text] [Related]
16. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience. Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333 [TBL] [Abstract][Full Text] [Related]
17. Locally advanced breast cancer: is surgery necessary? Favret AM; Carlson RW; Goffinet DR; Jeffrey SS; Dirbas FM; Stockdale FE Breast J; 2001; 7(2):131-7. PubMed ID: 11328324 [TBL] [Abstract][Full Text] [Related]
18. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA Breast J; 2006; 12(2):159-64. PubMed ID: 16509842 [TBL] [Abstract][Full Text] [Related]
19. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040 [TBL] [Abstract][Full Text] [Related]
20. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications. Datta NR; Rajkumar A; Basu R Indian J Cancer; 2003; 40(4):127-34. PubMed ID: 14716108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]